A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for Diffuse Large B-Cell Lymphoma
Drug: Rituximab
42 locations incl. Gilbert
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06717347·Phase 3·Recruiting